Dual or multi-targeting inhibitors: The next generation anticancer agents

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Standard cancer therapy involves combining inhibitors for specific single targets.
• Dual/multi-targeting agents, a single molecule acting on multiple targets, are emerging as a new therapeutic strategy.
• This approach addresses limitations of single-target therapies, including poor efficacy, safety profiles, and drug resistance.

Purpose of the Study:

• To review the discovery of dual-targeting agents for cancer therapy.
• To highlight the advantages of multi-targeting strategies over traditional combination therapies.
• To discuss rational, computational, and bioinformatics approaches in designing effective multi-target anticancer agents.

Main Methods:

• Review of recent literature on dual/multi-targeting agents in cancer therapy.
• Focus on rational drug design, computational methods, and bioinformatics tools.
• Exploration of polypharmacology and proteomic approaches for target identification and drug design.

Main Results:

• A growing body of research supports dual/multi-targeting as an efficient therapeutic strategy.
• Advances in bioinformatics and structural biology facilitate the design of multi-targeting molecules.
• Molecular docking and pharmacophore modeling are key techniques for discovering dual-targeting inhibitors.

Conclusions:

• Dual/multi-targeting agents represent a promising frontier in anticancer drug discovery.
• Rational design, aided by computational tools, is crucial for developing effective and safe multi-target drugs.
• This approach holds potential for overcoming challenges in current cancer treatment paradigms.